Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,301–1,400 of 3,116
Joshi, G. P. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005222 · Cited by 4
Coronary Artery Calcium Scoring Improves Allocation of the GLP-1 Receptor Agonist Semaglutide
Kloner, R. A., & Budoff, M. J. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.10.007 · Cited by 3
Future Medications for Obesity and Clinical Implications
Garvey, W. T. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0004 · Cited by 3
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 6
Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
Klein, K. R., Menacher, A., Buse, J. B., Mann, J. F. E., Tuttle, K. R., Kvist, K., Andersen, M. R., Mayrdorfer, M., & Lingvay, I. (2026) · Diabetes Care · doi:10.2337/dc26-0112 · Cited by 3
Self-citationMahmoud, A., Sheashaa, H., Killian, M., Awad, K., Ibrahim, R., Mahmoud, A., Farina, J., Abdelnabi, M., Kamel, I., Horn, B., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134588 · Cited by 3
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106951 · Cited by 6
Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists
Mensah, M. O., Freitas, D. J., & Cartwright, J. R. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2407932 · Cited by 3
Pham, H. N., Ibrahim, R., Abdelnabi, M. H., Bcharah, G., Mahmoud, A., Allam, M., Farina, J., Lee, J. Z., Singh, A., Ayoub, C., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf135 · Cited by 6
Li, D., Chen, Y., Zhu, X., Yang, Y., Li, H., & Zhao, R. C. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01098-3 · Cited by 7
Hamid, A., Minhas, A. M. K., Rizwan, A. M., Kamimura, D., Tio, M. C., Claudio, C. H., Pandey, A., Mentz, R. J., Nambi, V., Jones, D. W., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.01.025 · Cited by 3
A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use
Lam, C. Y., Lin, D., & Endlich, Y. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x241311597 · Cited by 4
Li, M., Wang, Y.-R., Wang, X., Xiao, X., Sun, Y.-H., Zhang, S., Dang, Y., Wang, K., & Zhou, W. (2025) · Pharmaceuticals · doi:10.3390/ph18121810 · Cited by 4
“However, this very mechanism underlies its major drawback: the concomitant activation of adipogenic transcription factors, particularly SREBP1, promotes adipocyte hypertrophy, hyperplasia, increased visceral fat mass, and significant weight gain [7,8].”
Dai, H., Lee, Y. A., Natalie, A., Jackson, W., PHAM, A., Levine, J., Radwan, R. M., Guo, J., Bian, J., & Sheer, A. J. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047893 · Cited by 6
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Putting More Weight on Obesity Trials in Heart Failure
Harrington, J., Sattar, N. A., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Pagidipati, N. J., Pandey, A., Spall, H. G. C. V., & McGuire, D. K. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00655-z · Cited by 3
Zhang, S., Niu, S., An, S., Cai, X., & Lao, X. Q. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178587 · Cited by 5
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD
Schattenberg, J. M., & George, J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101401 · Cited by 3
Zhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“…body of evidence indicates that elevated HR is an independent risk factor for cardiovascular events and mortality [13], a number of clinical studies and meta-analyses have demonstrated that the utilization of GLP-1RAs is associated with reduced incidence of cardiovascular events [47, 48].”
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3
Cherney, D. Z. I., Alicic, R. Z., & Bonaca, M. P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.01.010 · Cited by 7
Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation
Eun, Y., Bong, S., Koh, H. Y., Trousdale, R. K., Cho, Y. M., Jang, Y., & Lee, S. (2026) · Neurology · doi:10.1212/wnl.0000000000218174 · Cited by 4
Obesity: an overlooked player in cardiological practice and the need for urgent action
Ferrera, A., Battistoni, A., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad875 · Cited by 3
Brook, D., & SINGER, P. A. (2024) · medRxiv · doi:10.1101/2024.11.11.24317112 · Cited by 3
de Silva, R., & Cheng, K. C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae909 · Cited by 3
Garagoli, F., Masson, W. M., Barbagelata, L., & Lobo, M. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endinu.2025.501562 · Cited by 13
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Gosavi, R., Rasooli, M. A., Leon, N., Sivayogan, K., Koh, D., Hong, J. T., Narasimhan, V., & Ooi, G. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01405-1 · Cited by 3
“Although not studied in the included trials, these agents are gaining traction in the broader obesity literature for their efficacy in achieving sustained weight reduction, often in combination with dietary modification and physical activity [ 28, 29].”
Xu, Y., Huang, T., Zhang, Y., Ji, D., Tuttle, K. R., Carrero, J. J., & Fu, E. L. (2026) · Circulation · doi:10.1161/circulationaha.125.075157 · Cited by 7
GLP-1 receptor agonists—another promising therapy for Alport syndrome?
Boeckhaus, J., Mabillard, H. R., & Sayer, J. A. (2025) · Journal of Rare Diseases · doi:10.1007/s44162-024-00065-8 · Cited by 4
Hwang, S., Karhunen, V., Patel, A., Lockhart, S. M., Carter, P. R., Whittaker, J. C., & Burgess, S. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyaf223 · Cited by 3
Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians
Laroche, H. H., Fernández, C., Sweeney, B. R., Gillette, M. L. D., & Hampl, S. E. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0005 · Cited by 3
Phillips, W. T., & Schwartz, J. G. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1380632 · Cited by 5
Ajmera, R., Karim, H., Fegan, P. G., Dwivedi, G., & Lan, N. S. R. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.01.011 · Cited by 3
Vilsbøll, T., Kumar, D. A., Aiello, L. P., Rönnbäck, C., Stellfeld, M., & Larsen, L. M. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328729 · Cited by 10
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Muraoka, N., Jensen, M. B., Kartha, V. K., Carrico, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678829 · Cited by 3
Goodman, J., Schain, M., Stefano, G. D., Lupson, V. C., Horn, T., Hill, M., Manavaki, R., Fryer, T. D., Bumanlag-Amis, E., Jalaludeen, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04559-3 · Cited by 5
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen, A. S., Hajduk, A. M., Grimshaw, A. A., Fried, T. R., Jastreboff, A. M., & Lipska, K. J. (2024) · Obesity · doi:10.1002/oby.24160 · Cited by 8
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 5
Götzinger, F., Stolte, T., Reichl, J. J., von Peter, A., Kunz, M., Wild, M. G., Wagener, M., Kaiser, C., Mueller, C. E., Westermann, D., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag075 · Cited by 3
Drug approach to treatment for obesity in adults: perspectives and considerations
Escalada, J. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10206/2023 · Cited by 3
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Dong, J., Starkey, T., Cheng, V. W. T., Clark, J., Pinato, D. J., Robinson, T., Tilby, M., Turnbull, C. D., & Lee, L. Y. W. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102837 · Cited by 4
Wadden, T. A., Kushner, R. F., & Chao, A. M. (2024) · JAMA · doi:10.1001/jama.2023.28141 · Cited by 3
Self-citationConroy, L., McCann, A., Zhang, N., & de Gaetano, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00695.2023 · Cited by 5
Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-06245-w · Cited by 8
Ruchko, E., Maria, C., Sokolov, V., Starinnov, Z. R., Sabirov, M. S., & Vasiliev, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1698296 · Cited by 4
“Clinical evidence shows that GLP1R agonists not only improve glycemic control but also exert beneficial effects on body weight and the cardiovascular system, as confirmed in large-scale trials of agents such as Liraglutide (Marso et al., 2016), Dulaglutide (Gerstein et al., 2019), and Semaglutide (Lincoff et al., 2023…”
The promise and hope of GLP-1 receptor agonists
Sumithran, P., & Ard, J. D. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00315-2 · Cited by 4
ROSENSTOCK, J., Lingvay, I., RYAN, D. H., Jastreboff, A. M., Kushner, R., ACOSTA, A., Blevins, T., Choi, M., HOLMES, F. L., Smith, T., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04476-6 · Cited by 9
“Other cardiovascular risk factors were also notably improved with aleniglipron treatment, such as systolic blood pressure, hsCRP and HbA1c, which could positively contribute to the known cardiovascular benefits and potential diabetes-prevention effects of approved GLP-1RAs 6,8,11 .”
Self-citationCardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice
Medamana, J. L., Gelfand, J. M., Weber, B., & Garshick, M. S. (2025) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001092 · Cited by 5
Chrzanowski, J., Walicka, M., Burzyński, J., Zaraś, M., Michalak, A., & Fendler, W. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005064 · Cited by 8
“Its use is supported by robust evidence showing substantial reductions in cardiovascular risk [4–9], and semaglutide is now recommended in many international guidelines [10–13].”
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Ramadurgum, P., Sharma, K. M., Pinon, A., Kattamuri, L. P. V., & Botros, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02356-6 · Cited by 3
Wong, N. D., Karthikeyan, H., & Fan, W. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07583-z · Cited by 3
“Recently reported and ongoing cardiovascular outcomes therapies of newer obesity therapies [11, 22] will document true efficacy of these agents in improving CVD outcomes in persons who are overweight or with obesity.”
InfluentialSritharan, S., Murray, K., Lam, D., Wittaker, D., Sverdlov, A. L., Boyle, A. J., Davies, A. J., Williams, T. D., & Collins, N. P. (2025) · Internal Medicine Journal · doi:10.1111/imj.16617 · Cited by 3
Emerging drug delivery strategies for local immunomodulation in atherosclerosis
Nunes, C., Kramer, A., & Volpatti, L. R. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114261 · Cited by 6
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Advances in postpartum hypertension management: a review of current guidelines and interventions
McCoy, S. E., Hurwitz, M., Kwapong, Y. A., Bircan, E., Spitz, J. A., Dastmalchi, L. N., Metlock, F., Saad, A. F., Sarma, A. A., Khandelwal, A., et al. (2025) · npj Women s Health · doi:10.1038/s44294-025-00095-7 · Cited by 11
Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions
Leong, A. M., Arnold, A. D., & Whinnett, Z. I. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11030092 · Cited by 6
The knowns and unknowns of glucagon-like peptide 1 agonists and perioperative care
McIsaac, D. I., Valencia, M. I. B., & Miller, E. C. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-024-02718-0 · Cited by 4
Foscue, E. P., Trinko, R., Jiménez, J. L., Kong, E., Thompson, S. L., Stankewich, K., Corstens, A. M., Serlie, M. J. M., Taylor, J. R., & Dileone, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.08.681212 · Cited by 6
“These GLP-1–based agents significantly improve health outcomes, in part by reducing risks for cardiometabolic and obesity-related comorbidities (LincoV et al., 2023).”
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
Verma, S., Cosentino, F., & Kosiborod, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae744 · Cited by 3
Perioperative Considerations for Patients on GLP1 Agonists
VanderWielen, B. A., & Beam, W. B. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.002 · Cited by 3
Obesity and Comorbidity Management in Psoriatic Arthritis
Maharaj, A. B., Eder, L., & Ogdie, A. (2025) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2025.07.001 · Cited by 4
Animal Models of Exercise and Cardiometabolic Disease
Dong, G., RYAN, T. E., & Esser, K. A. (2025) · Circulation Research · doi:10.1161/circresaha.124.325704 · Cited by 6
Burrello, J., Melo, M. G., Taheri, A., Nagler, M., Airale, L., Burrello, A., Goi, J., Kraljević, M., Delko, T., Dietrich, E., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf561 · Cited by 3
Chartoumpekis, D. V., Chen, I., Salvatore, S. R., Schopfer, F. J., Freeman, B. Α., & Khoo, N. K. H. (2024) · Nitric Oxide · doi:10.1016/j.niox.2024.06.002 · Cited by 4
Italian Association of Hospital Cardiologists position paper—obesity in adults: a clinical primer
Fusco, S. A. D., Mocini, E., Gori, M., Iacoviello, M., Bilato, C., Corda, M., Luca, L. D., Marco, M. D., Geraci, G., Iacovoni, A., et al. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae031 · Cited by 3
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Management of Obesity in Psoriasis Consultations
Nicolau, J., López‐Ferrer, A., & de la Cueva, P. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01664-7 · Cited by 5
“However, improvements in weight and other cardiovascular risk factors, such as waist circumference, blood pressure, lipid profile, and circulating C‑reactive protein levels, accounted for only 31.4% of the reduction in cardiovascular events [13, 47–49].”
InfluentialEconomos, H., & MacIsaac, R. J. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.109457 · Cited by 5
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“The SELECT [88] trial was a large, randomized, placebo-controlled cardiovascular outcomes trial (CVOT) that enrolled 17,604 patients with established atherosclerotic cardiovascular disease (ASCVD) and either obesity or overweight (BMI ≥ 27 kg/m 2 ) but without diabetes.”
InfluentialChoudhury, I., Ward, J. H., Mahesh, S., Alam, U., Azmi, S., & Anson, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.02.010 · Cited by 5
Tănăsescu, M., Rosu, A.-M., Mincă, A., Rosu, A.-L., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026) · Life · doi:10.3390/life16010172 · Cited by 12
“Treatments initially developed for glycemic control have been shown to reduce cardiovascular events, heart failure risk, and kidney disease progression, supporting the concept that shared metabolic pathways underlie clinical events across these systems [18–20].”
InfluentialThiara, D. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0237 · Cited by 3
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
An, K. R., Sandner, S. E., Redfors, B., Alexander, J. H., Alzghari, T., Caldonazo, T. M. M., Cancelli, G., Dell'Aquila, M., Dimagli, A., Gibson, C. M., et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae221 · Cited by 7
Proposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk Factors
Reddy, K. R., Faridi, K. F., Aggarwal, M., Tirumalai, A. A., Singh, T. K., Tejtel, S. K. S., Williams, K. A., Sr., Litwin, S. E., Dastmalchi, L. N., White, B. A., et al. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241269532 · Cited by 3
Song, C., Qiao, Z., Cheng, J., Zhang, Y., Liu, W., Yuan, S., He, J., Song, Y., Bian, X., Lin, Z., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037492 · Cited by 5
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Cercato, C., Stumpf, M. A. M., Freire, G. N. D. C., Kawahara, E. Z., Fernandes, A. E., de Melo, M. E., & Mancini, M. C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01842-1 · Cited by 4
Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment
Zoccali, C., Caterina, R. D., Tuttle, K. R., Burnier, M., Massy, Z. A., Mallamaci, F., Ferro, C. J., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag220 · Cited by 5
Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis
Ballestero, S. B., Yttergren, S. T., Hahn, M., Rosenkilde, M. B., Jensen, D. M., Christensen, M. S., Thisted, L., Holmberg, H. L., Teixeira, G., Biering‐Sørensen, T., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70217 · Cited by 4
Hip and Knee Arthroplasty in Patients with Obesity
Koh, C. K., Garceau, S. P., Grammatopoulos, G. A., & Beaulé, P. E. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.00131 · Cited by 3
Kjærgaard, J., Møller, C. H., Wiberg, S. C., Mikkelsen, A. D., Møller‐Sørensen, H., Ravn, H. B., Ravn, J. B., Olsen, P. S., Høfsten, D. E., Boesgaard, S., et al. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.124.014961 · Cited by 7
Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines
Platz, E., Peikert, A., Bozkurt, B., der Schueren, B. V., Butler, J., Lingvay, I., McGuire, D. K., Zannad, F. M., & Sattar, N. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.013 · Cited by 3
Self-citationGál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6
Targeting Obesity for Heart Failure
Morris, E., & Rider, O. J. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.37 · Cited by 3
“64 Notably, semaglutide benefited both HFpEF and HFrEF patients, with no significant heterogeneity in outcomes between these groups.”
Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?
Weir, M. R. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151688 · Cited by 4
Kanu, C., Boye, K. S., Poon, J. L., GOETZ, I. A., WILLIAMSON, S. E., Lou, J., Hartman, M. L., Martin, C. K., & Coşkun, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70097 · Cited by 6
Treatment of Obesity in Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.016 · Cited by 3
What the SELECT trial of semaglutide means for clinicians
Sattar, N. A., Lee, M. M. Y., & McGuire, D. K. (2024) · Nature Medicine · doi:10.1038/s41591-024-03013-7 · Cited by 4
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Gabery, S., Glendorf, T., Ballarín-González, B., Pedersen, K., Kruse, T., Raun, K., & Kuhre, R. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123845 · Cited by 4
Chen, J., Fang, Y., Liu, Y., Chen, M., & Tsai, M. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70187 · Cited by 6
“…of Cardiovascular Outcome Results (LEADER) [14], Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) [15], and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) [16] have shown reduced major adverse cardiovascular events…”
Glucagon‐like peptide‐1 receptor agonists in the perioperative period: to cease or not to cease?
Martis, W. R., Sachithanandan, N., Chiang, C. Y., & Riedel, B. (2023) · ANZ Journal of Surgery · doi:10.1111/ans.18804 · Cited by 3
Efecto de la liraglutida en pacientes con artritis psoriásica y obesidad
Nicolau, J., Nadal, A., Ros, I., et al. (2025) · Reumatología Clínica · doi:10.1016/j.reuma.2024.501809 · Cited by 3
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
Phizackerley, D. (2024) · BMJ · doi:10.1136/bmj.q53 · Cited by 3
Malahfji, M., & Al-Mallah, M. H. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118523 · Cited by 3
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
